Bourrié, B <br/><br/>
The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.  [electronic resource] 

 -  Proceedings of the National Academy of Sciences of the United States of America  Oct 1999 
 - 12855-9 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0027-8424 
<br/><br/><label>Standard No.: </label>10.1073/pnas.96.22.12855  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Animals<br/>Blood-Brain Barrier<br/>Cytokines--metabolism<br/>Encephalomyelitis, Autoimmune, Experimental--drug therapy<br/>Female<br/>Lipopolysaccharides--administration & dosage<br/>Multiple Sclerosis--drug therapy<br/>Naphthalenes--administration & dosage<br/>Neuroprotective Agents--administration & dosage<br/>Pyridines--administration & dosage<br/>Rats<br/>Rats, Inbred Lew<br/>Th1 Cells--immunology<br/>Th2 Cells--immunology<br/>Tumor Necrosis Factor-alpha--biosynthesis